Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Current Income Tax Expense (Benefit)

2.8 / 5 stars · 68/120 Roast Me

Cartesian Therapeutics, Inc. Current Income Tax Expense (Benefit)

Cartesian Therapeutics, Inc. (RNAC) reported Current Income Tax Expense (Benefit) of $300.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.

Financial Statements › Expense Statement › Income Tax

us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2025-03-13

  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2018-12-31 was $0.00.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2018-09-30 was $0.00.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2018-06-30 was $0.00.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2018-03-31 was $0.00.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for fiscal 2024 was $300.00K.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for fiscal 2023 was -$19.00M.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for fiscal 2022 was -$600.00K, a 103.75% decline from fiscal 2021.
  • Cartesian Therapeutics, Inc. current income tax expense (benefit) for fiscal 2021 was $16.00M.
Period endCurrent Income Tax Expense (Benefit) 3 monthCurrent Income Tax Expense (Benefit) 6 monthCurrent Income Tax Expense (Benefit) 9 monthCurrent Income Tax Expense (Benefit) 12 monthCurrent Income Tax Expense (Benefit) 12 month as first filed
2024-12-31$300.00K
10-K · filed 2025-03-13
2023-12-31-$19.00M
10-K · filed 2025-03-13
2022-12-31-$600.00K
10-K · filed 2024-03-07
$16.00M
10-K · filed 2023-03-02
2021-12-31$16.00M
10-K · filed 2024-03-07
2018-12-31$0.00
10-K · filed 2019-03-15
$0.00
derived: sum of 2 quarters · filed 2019-03-15
$0.00
derived: sum of 3 quarters · filed 2019-03-15
$0.00
10-K · filed 2019-03-15
2018-09-30$0.00
10-Q · filed 2018-11-08
$0.00
derived: sum of 2 quarters · filed 2018-11-08
$0.00
10-Q · filed 2018-11-08
$0.00
derived: sum of 4 quarters · filed 2019-03-15
2018-06-30$0.00
10-Q · filed 2018-08-08
$0.00
10-Q · filed 2018-08-08
$0.00
derived: sum of 3 quarters · filed 2019-03-15
$0.00
derived: sum of 4 quarters · filed 2019-03-15
2018-03-31$0.00
10-Q · filed 2018-05-09
$0.00
derived: sum of 2 quarters · filed 2019-03-15
$0.00
derived: sum of 3 quarters · filed 2019-03-15
$0.00
derived: sum of 4 quarters · filed 2019-03-15
2017-12-31$0.00
10-K · filed 2019-03-15
$0.00
derived: sum of 2 quarters · filed 2019-03-15
$0.00
derived: sum of 3 quarters · filed 2019-03-15
$0.00
10-K · filed 2019-03-15
2017-09-30$0.00
10-Q · filed 2018-11-08
$0.00
derived: sum of 2 quarters · filed 2018-11-08
$0.00
10-Q · filed 2018-11-08
2017-06-30$0.00
10-Q · filed 2018-08-08
$0.00
10-Q · filed 2018-08-08
2017-03-31$0.00
10-Q · filed 2018-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23